---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-035699"
form_type: "8-K"
ticker: "ADGM"
cik: "0002006986"
company_name: "Adagio Medical Holdings, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:43:09.714261+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Adagio Medical reports FY2025 net loss $25.1M; FULCRUM-VT trial fully enrolled with 97% acute effectiveness

## Summary
- Net loss of $25.1M for FY2025, down from $75.0M in FY2024; Q4 net loss $3.3M vs $57.4M.
- Completed enrollment of 209-patient FULCRUM-VT pivotal IDE trial; preliminary 97% acute effectiveness.
- Closed private placement with gross proceeds up to $50M; upfront $19M to fund FDA submission.
- Cash and equivalents $17.1M as of Dec 31, 2025; no revenue reported.
- Appointed former Medtronic executive Sean Salmon to Board; added senior sales and manufacturing VPs.

## SEC filing metadata
- accession: 0001104659-26-035699
- form_type: 8-K
- ticker: ADGM
- cik: 0002006986
- company_name: Adagio Medical Holdings, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/0001104659-26-035699-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2006986/000110465926035699/adgm-20260326x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-035699
- JSON: https://secwatch.observer/filing/0001104659-26-035699.json
- Plain text: https://secwatch.observer/filing/0001104659-26-035699.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.